Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Obtains FDA Approval For Penicillin G Potassium For Injection
APP Pharmaceuticals (APP) has received approval from the FDA to market Penicillin G Potassium for Injection, USP, in two dosage strengths. Penicillin G is used to treat a
APP Pharmaceuticals (APP) has received approval from the FDA to market Penicillin G Potassium for Injection, USP, in two dosage strengths. Penicillin G is used to treat a
Peptimmune has completed phase Ib study of PI-2301. The trial was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301, in subjects with Secondary Progressive Multiple
Amgen has reported the top-line results of phase 3 study of Aranesp. Aranesp is for the treatment of anemia associated with CRF for patients on dialysis and patients
Pfizer has opened a new biotech facility in Sweden, which will be used to make products including a branded version of human growth hormone. The company said that
Profectus BioSciences (Profectus) has signed a research collaboration agreement with the Path Malaria Vaccine Initiative (MVI), to conduct proof-of-concept studies with its recombinant vesicular stomatitis virus (rVSV) vector
GlaxoSmithKline (GSK) has issued a statement in response to the FDA’s Early Communication about the safety review of orlistat. The company said that the FDA is reviewing data
Morria Biopharmaceuticals has received written approval to initiate phase II clinical trial on its topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study on 80 contact
Sinochem Quanzhou Petrochemical (Sinochem Quanzhou) has selected UNIPOL Polypropylene Process Technology for its new 200 KTA polypropylene facility. The plant will be built in Quanzhou, Fujian Province in
US-based Merck has reported that the European Medicines Agency (EMEA) has accepted to review the company’s Marketing Authorisation Application (MAA), for the regulatory approval of vernakalant intravenous (IV).
AVI BioPharma has revealed the results and scientific findings of its phase 1 clinical trial assessing the proof of concept and safety of AVI-4658 in patients with Duchenne